Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
2(17%)
Results Posted
67%(4 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
7
58%
Ph phase_2
5
42%

Phase Distribution

7

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
7(58.3%)
Phase 2Efficacy & side effects
5(41.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

12

all time

Status Distribution
Active(2)
Completed(6)
Terminated(2)
Other(2)

Detailed Status

Completed6
Active, not recruiting2
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
2
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (58.3%)
Phase 25 (41.7%)

Trials by Status

completed650%
active_not_recruiting217%
terminated217%
unknown217%

Recent Activity

2 active trials
Showing 5 of 12
completedphase_2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

NCT02664935
active_not_recruitingphase_1

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
active_not_recruitingphase_2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

NCT02299999
completedphase_2

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

NCT02117167
completedphase_1

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

NCT01824901
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02664935Phase 2

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Completed
NCT02546661Phase 1

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Active Not Recruiting
NCT02299999Phase 2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active Not Recruiting
NCT02117167Phase 2

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed
NCT01824901Phase 1

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Completed
NCT05775874Phase 2

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Unknown
NCT05086666Phase 1

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Unknown
NCT02824133Phase 1

Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"

Completed
NCT00979134Phase 1

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Terminated
NCT01457846Phase 2

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

Terminated
NCT01213160Phase 1

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Completed
NCT01202591Phase 1

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12